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Introduction: Muscle atrophy results from a dysfunction in protein turnover that leads to loss of 
mass and function and occurs concurrently with multiple pathologies such as cancer and 
extended bed rest. Atrophy reduces overall quality of life while increasing morbidity and 
mortality. Currently, efficacious therapeutic interventions to treat and prevent muscle wasting in 
all its forms are lacking, however if conserved mechanisms can be identified between wasting 
conditions, this would aid in the development of multipurpose therapeutics to ameliorate this 
pathology. Purpose: To examine circulating factors present across atrophic pathologies. 
Methods: 35 Male C57BL/6J mice were assigned to hindlimb unloading (HU), Lewis Lung 
Carcinoma (LLC), or control groups. HU animals were hindlimb-unloaded for 1 week to induce 
disuse atrophy. LLC cells were injected into the right hind-flank to induce cancer cachexia. 
Tumors developed for approximately 4 weeks. Age-matched mice were humanely euthanized 
after experimental intervention. Muscle and plasma were collected for analysis. Plasma was 
analyzed by tandem mass tag (TMT) proteomics. Results: Raw plantaris weight was 
significantly lower in LLC (22.7%) and HU (18.6%) groups compared to control (p<0.05), but 
not different from each other (p>0.05). Equivalent tibia sizes across groups suggest no 
significant differences in body size. In the LLC-HU comparison, 104 proteins were differentially 
expressed (DE). 44 were up-regulated and 60 were down-regulated. In the LLC-CON 
comparison, 91 DE proteins were observed. Of these, 39 were up-regulated and 52 were down-
regulated. In the HU-CON comparison, 5 DE proteins were up-regulated and 4 were down-
regulated; a total of 9 DE proteins were observed. Several signaling pathways were implicated in 
this analysis including the acute phase response signaling system and liver X receptor/retinoid X 
receptor (LXR/RXR) and farnesoid X receptor/retinoid X receptor (FXR/RXR) activation. 
 
 
Conclusion: Plasma proteomic profiles are altered in cancer cachexia and disuse-induced 
atrophy. Modulated protein profiles suggest the possibility of multi-tissue involvement in muscle 
atrophy. Future experiments are required to understand how plasma proteins and muscle interact 
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Chapter 1: Literature Review 
Muscle Atrophy Overview 
 Muscle atrophy is a pathological dysfunction in protein turnover where an imbalance in 
protein synthesis and degradation leads to an overall loss in muscle mass and muscle function 
(32). Atrophy is a serious condition that is often experienced as a side effect of many other 
diseases including cancer, AIDS, sepsis, muscular dystrophies and chronic inflammatory 
diseases, and states of disuse such as casting, forced bed rest, or space flight. Unfortunately, 
atrophy is also exacerbated by drugs intended to treat some of those same diseases, including 
common chemotherapeutics such as dexamethasone (26, 47). Atrophy, also commonly referred 
to as muscle wasting, increases morbidity and mortality in these patients while significantly 
reducing quality of life (45). Currently, safe and efficacious therapeutic interventions to treat and 
prevent muscle wasting are lacking. Therefore, the objective of this review will be to examine 
the different forms of muscle wasting and what factors influence the mechanism of these various 
etiologies.     
Types of Muscle Wasting 
 Muscle atrophy stems from several etiologies including cancer cachexia, disuse, 
denervation, dystrophy, sarcopenia, and sepsis. However, skeletal muscle does not respond to 
these conditions in the same manner. Cancer cachexia occurs secondary to tumors. Patients with 
gastric and pancreatic cancers are particularly vulnerable to developing cachexia (21). These 
conditions elevate the immune response in the body, creating an inflammatory environment. 
Cancer cachexia primarily affects type II fibers (11). In contrast to cachexia, muscle unloading 
via forced bed rest, casting, and space flight does not lead to inflammation. In this environment, 
type I fibers are more susceptible to wasting (15). Denervation is an atrophy model that 
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recapitulates spinal cord injury. The wasting that occurs secondary to denervation is similar to 
disuse. Inflammation is not induced, and type I fibers are primarily afflicted (15). Duchenne’s 
muscular dystrophy is a genetic disorder that disrupts the linkage of the muscle cell’s contractile 
apparatus to the extracellular matrix (15, 30). This disorder causes severe muscle damage, 
inflammation, and premature death (16). Fiber types are not discriminated in muscular 
dystrophy. Sarcopenia is an age-related condition that leads to the loss of muscle mass (18). In 
this condition, inflammation is elevated and, similar to cancer cachexia, type II fibers are the 
primary target of wasting (35). Sepsis is a life-threatening organ dysfunction secondary to a 
dysregulated host response to an infection (56). In order to protect itself from the infection, the 
body dramatically elevates its inflammatory response (51). While this is necessary for survival, it 
is detrimental to skeletal muscle tissue, particularly type II fibers (66). Atrophy occurs under 
many circumstances and the skeletal muscle exhibits divergent responses to these stimuli. 
Therefore, the remainder of this review will focus on comparing cancer cachexia and disuse-
induced atrophy.     
Cancer Cachexia 
 Cancer cachexia is characterized by a significant loss in body weight due to decreases in 
muscle mass, with or without fat loss. Cachexia is currently responsible for approximately 20%-
40% of cancer deaths (22). Patients with gastric or pancreatic cancers are especially prone to 
cachexia (23). It was originally thought that decreased nutritional intake was largely responsible 
for the development of cachexia. However, current evidence suggests that resolving hypophagia 
is not sufficient to prevent and reverse cachexia (29). This is an extremely complex metabolic 




Significant evidence suggests that protein anabolism is reduced in cachexia (7, 11, 57, 59, 
61, 69). For example, Smith and Tisdale (57) utilized a MAC16 adenocarcinoma injectable 
cancer model to examine the effect of cancer on protein turnover. The authors implanted mice 
with a tumorigenic strain of cells. After 10-12 days of implantation, the authors observed 
palpable tumors. Animals were sacrificed and gastrocnemii were harvested for protein turnover 
analysis using radioactive labeling techniques. They observed that a body weight loss of 15%-
30% corresponded to a 60% decrease in protein synthesis. Similarly, Samuels et al. (50) utilized 
a C26 adenocarcinoma cancer model to examine the effect of cancer cachexia and chemotherapy 
on protein synthesis and degradation. The authors employed the flooding dose method to 
measure protein turnover in vivo. They found that after the onset of cancer cachexia, mice 
exhibited significant reductions in protein synthesis. The incorporation of the chemotherapeutic 
agent cystemustine rescued protein synthetic rates in tumor bearing animals. At this point, there 
is a consensus that protein synthesis is down regulated in cancer cachectic subjects.   
This decrease in protein synthetic rate is likely due to the down-regulation of several 
anabolic factors including insulin-like growth factor 1 (IGF-1), Akt, mTOR, and satellite cells 
(22, 58). IGF-1, Akt, and mTOR are connected in a prominent PI3K/Akt protein synthetic 
pathway. In healthy conditions, insulin binds IGF-1 which leads to a conformational change in 
the receptor and phosphorylates intracellular IRS-1. Activated IRS-1 causes a cascade of 
phosphorylation events that activates Akt and leads to the activation of mTOR. Phosphorylated 
mTOR is associated with a dissociation of binding protein 4E-BP1 from the eukaryotic initiation 
factors 4G and 4E that form a scaffold and bind to the 5’ region of mRNA. This dissociation 
allows for the binding of 4A and the formation of the 4F complex that allows for ribosomal 
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recruitment and mRNA translation (55). A down-regulation of any of these factors will 
negatively influence protein synthesis. Satellite cells are unipotent stem cells necessary for 
muscle maintenance, repair, and hypertrophy (20). When signaled by damage, satellite cells 
proliferate, differentiate, and migrate to the site they are required. A decrease in the available 
pool of satellite cells limits muscle growth and repair. A perturbation in any of these anabolic 
factors will limit or reduce overall protein synthetic rates in afflicted muscle.   
Protein Catabolism 
 The available literature suggests that protein catabolism is elevated in cancer cachexia 
(11, 60, 62, 69,72). Smith and Tisdale (57) observed a significant increase in protein degradation 
with a 16%-20% weight loss. They measured protein degradation in situ in the gastrocnemius via 
radioactive labeling techniques. They reported a maximal increase of catabolism at 240% from 
healthy conditions when weight loss was at 30%. Additionally, Samuels et al. (50) observed 
significant increases in protein degradation at the onset of cachexia. Their chemotherapeutic 
agent did not increase this effect. It is worth noting that they measured degradation indirectly by 
extrapolating the relationship between growth and synthesis. Studying protein degradation is 
difficult, but there seems to be a consensus that catabolism is significantly elevated under 
cachectic conditions (32).  
 This elevation in degradation may be due to the up-regulation of several catabolic 
markers including cytokines, myostatin, forkhead box O (FoxO), reactive oxygen species (ROS), 
nuclear factor (NF-ĸB), and proteolysis inducing factor (PIF) (22, 58). NF-ĸB is one of the 
primary transcription factors that transduces (tumor necrotic factor) TNF-α signals into cells. 
NF-ĸB is also responsible for activating the gene expression of other cytokines. Together, tumor 
factors and cytokines up-regulate the ubiquitin-proteasome system, promoting protein 
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degradation. FoxO transcription factors also play a major role in catabolism. In healthy 
conditions, FoxO is phosphorylated by PI3K/Akt and is inactivated. In its active conformation, 
FoxO translocates to the nucleus and up-regulates the expression of skeletal muscle specific E3 
ubiquitin ligases muscle RING-finger protein-1 (MuRF1) and atrogin-1/muscle atrophy F-box 
(MAFbx). FoxO also up-regulates the expression of other autophagy related genes LC3 and 
Bnip3. The FoxO system is influenced by ROS, PIF, and IGF-1, all of which are modulated by 
cachexia. PIF plays an additional role in catabolism as it is shown to inhibit mRNA translation 
via phosphorylation of the eukaryotic initiation factor 2α. Myostatin also contributes to 
cachexia’s catabolic effect. Myostatin is a well-known protein responsible for negatively 
regulating muscle mass. In healthy conditions, myostatin expression is regulated by IGF-1. 
However, due to the down-regulation of IGF-1 in cachexia, myostatin can be overexpressed, 
attenuating muscle growth and contributing to a loss in muscle mass (58). Several pathways are 
involved in protein catabolism. The pathologic modulation of these pathways contributes to an 
undesired up-regulation of protein degradation.  
Energy Metabolism 
 Mitochondria are crucial for energy metabolism in skeletal muscle. However, it is not 
enough to consider mitochondria as the ‘powerhouse of the cell” without also considering 
mitochondrial quality which relates to the overall health and function of the mitochondrial 
network. An impaired mitochondrial network produces less ATP and significantly more reactive 
oxygen species (ROS) which is detrimental to cell health (1). The mitochondria regulate network 
quality through various processes. These include the biogenesis of new mitochondrial materials, 
the incorporation of new material and removal of dysfunctional mitochondria via fusion and 
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fission (dynamics), and the autophagic removal of mitochondria that have been removed from 
the network (mitophagy) (49, 73).  
 Evidence suggests that the mitochondrial network is impaired in cancer cachexia and may 
play an initiating role (10, 33, 43, 44, 64). Brown et al. (10) utilized the ApcMin/+ genetic model 
for colorectal cancer and a Lewis Lung Cancer (LLC) injectable cancer model to understand the 
cellular events that occur in the development of cancer cachexia. A cachectic phenotype was 
observed 4 weeks post-injection in the LLC animals. However, mitochondrial respiration was 
significantly decreased at 3 weeks and ROS production was significantly increased at 1 week. 
We electroporated the right flexor digitorum brevis with the fluorescent reporter gene 
pMitoTimer to observe mitochondrial quality via fluorescence microscopy (36). In the presence 
of this reporter protein, healthy mitochondria fluoresce green while unhealthy mitochondria 
oxidize the protein and fluoresce red. This allows the red:green ratio in these images to be 
analyzed to determine mitochondrial quality. At 2 weeks, mitochondrial quality was 
compromised in these animals. Marzetti et al. (38) performed a study in human cancer cachectic 
patients and observed perturbations in gene expression related to the regulation of mitochondrial 
quality. The authors performed muscle biopsies on the rectus abdominus of their subjects 
(control, cancer, cancer cachexia groups). They observed that fusion protein Mfn2 was down-
regulated in both cancer groups regardless of cachexia diagnosis. However, they found that the 
fission protein Fis1 was significantly up-regulated only in the cachexia cohort. They did not note 
any significant differences in the expression of the master regulator of biogenesis, PGC-1α. 
Interestingly, mitophagy proteins PINK1 and Parkin were significantly down-regulated in both 
cancer conditions which may suggest impaired or failed mitophagy. Remarkably, the 
upregulation of Fis 1 corresponds to observations made by Brown et al. (10) in LLC cachectic 
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mice. Regardless of species, there is evidence that degeneration of mitochondria is involved in 
the pathogenesis of cancer cachexia.     
Disuse-Induced Atrophy 
 Disuse-induced atrophy is common in forced bed-rest, limb casting, and space flight (4). 
In these conditions, atrophy is associated with the lack of muscular tension, or unloading. 
Whether temporary or prolonged, this disuse can have deleterious effects on force production 
and increase mortality and morbidity. There are currently no interventions, pharmaceutical or 
otherwise, available to treat or prevent this disorder. While disuse atrophy is not associated with 
the inflammation commonly observed in cachexia, protein anabolism, protein catabolism, and 
energy metabolism are all affected (48).    
Protein Anabolism 
  The literature suggests that protein synthetic rates are blunted by disuse-induced atrophy 
(34, 48, 54). Kazi et al. (34) examined disuse atrophy in hindlimb suspended C57BL/6J mice. 
The gastrocnemii were harvested and flooding dose methodology was used to determine protein 
synthesis following 3 days of suspension. At this time point, muscles had wasted and protein 
synthesis was significantly decreased. According to their data from DEPTOR knockdown 
animals, it appears that this decrease in anabolism is likely due to mTOR mediated synthesis 
inhibition. Similarly, Baehr et al. (5) examined the muscle-specific and age-related changes in 
protein synthesis and degradation in response to hindlimb suspension in rats. The authors were 
also able to detect wasting in the gastrocnemius after 3 days of suspension. Protein synthesis was 
assessed using the SuNSET method. Anabolism was decreased in all hindlimb muscles at 3 and 7 
days. The synthetic rate in the soleus remained low at 14 days.  These data suggest a fiber type 
dependent response to protein anabolism. 
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 The mTOR pathway is a critical regulatory system for protein anabolism which is 
negatively impacted by disuse (4, 54). Specifically, Kazi et al. (34) suggest that knocking down 
DEPTOR, an mTOR inhibitor, can rescue protein synthesis in hindlimb unloading. It is known 
that acute immobilization can alter the expression of more than 600 mRNAs, but their exact 
effects remain essentially unexplored. Promising targets have emerged from this data. Two 
transcription factors, activating transcription factor 4 (ATF4), and p53 are up-regulated in 
atrophy. These proteins are shown to be sufficient in the generation of atrophy. Additionally, 
p21, an inhibitor of cyclin-dependent kinases is up-regulated in immobilization induced atrophy. 
Downstream from p21 is spermine oxidase. It appears that the up-regulation of p21 leads to the 
inhibition of spermine oxidase and, in turn, atrophy (4). These discoveries are potentially 
impactful in developing treatments for atrophy. However, more work is needed to determine the 
mechanism through which these proteins act on skeletal muscle in wasting conditions. Though 
the data do not completely agree, it seems that protein synthesis is blunted to a degree in most 
tissues upon unloading. 
Protein Catabolism 
 Baehr et al. (5) examined both protein synthesis and degradation. They indirectly 
observed catabolism by analyzing the activities of catabolic markers proteasome and cathepsin 
L. They suggest that catabolism was increased in the soleus and tibialis anterior muscles of adult 
rats. They did not observe any changes in catabolic markers in older animals. This suggests an 
age and fiber type-modulated response to hindlimb unloading. Overall, protein metabolism is 
affected in unloaded animals. The degree to which anabolism and/or catabolism contributes 
appears to depend on several factors including age, fiber type, and duration of unloading.  
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 mRNA evidence suggests an up-regulation of the catabolic factors MuRF1, MAFbx, 
FoxO, and FoxO3a in unloading-induced atrophy (4). Insulin resistance will attenuate the 
PI3K/Akt pathway, leaving FoxO in its active conformation. As previously described (22, 58), 
FoxO will translocate to the nucleus and up-regulate the transcription of E3 ubiquitin ligases 
MuRF1 and MAFbx. However, it is suggested that the expression of these markers is dependent 
on the muscle being studied and its time spent unloaded. More work is needed to elucidate the 
importance of these potential metabolic pathways.   
Energy Metabolism 
 As previously discussed, proper mitochondrial function is imperative to cellular health 
(46). Cannavino et al. (14) examined the influence of PGC-1α overexpression on hindlimb 
unloaded mice. They used C57BL/6J and transgenic mice that overexpressed the mitochondrial 
biogenesis protein PGC-1α in the skeletal muscle. These animals were suspended for 3, 7, and 14 
days. At the given time points, animals were sacrificed and gastrocnemii were harvested for 
analysis. They found that fusion was impaired in WT animals that had been suspended for 3 
days. A change in the oxidative capacity of the muscle suggested impaired mitochondrial 
function. This dysfunction led to AMPK induced autophagy. They also found that PGC-1α 
overexpression preserved muscle mass in unloaded conditions. Additionally, overexpression 
prevented dysfunction of mitochondrial fusion and prevented catabolism via the AMPK 
pathway. The same laboratory examined the interaction between PGC-1α, mechanical unloading, 
and the soleus (13). Similar to their other findings, hindlimb unloading leads to muscle wasting. 
In this model, a redox imbalance was observed after unloading. Hindlimb suspension induced 
catabolic pathways and reduced protein synthetic rates. The authors tried to prevent catabolism 
in WT animals by treating them with the antioxidant Trolox, a vitamin E analog. They found that 
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this treatment did not play a preventative role in the induction of catabolic systems. Not 
surprisingly, oxidative metabolism was impaired after unloading. The authors observed that 
elevated PGC-1α expression protected soleus CSA, even after mechanical unloading had 
occurred. This overexpression prevented catabolism without impacting protein synthesis.  
These data suggest mitochondrial involvement in disuse-induced atrophy independent of 
fiber-type. Moreover, the mitochondria represent a significant contributor to and potential 
initiator of atrophy. This warrants further study of mitochondria as a potential therapeutic target 
in wasting secondary to mechanical unloading.  
Plasma Interactions 
 Plasma connects the cardiovascular system to every other system in the body. It circulates 
oxygen introduced by the respiratory system, nutrients absorbed through the digestive system, 
and hormone signals secreted by endocrine glands to target tissues. Because cancer cachexia is a 
multi-organ syndrome that affects adipose, liver, heart, and skeletal muscle, there is potential for 
cachectic muscle to be modulated via circulated factors (3, 67). In fact, evidence suggests that 
the pro-inflammatory cytokine Interleukin 6 (IL-6) is up-regulated in the plasma of cancer 
cachectic patients (9, 70). The value of proteomic profiles in biological fluids as a diagnostic tool 
and source of potential treatment targets is beginning to be appreciated (19). Performing a global 
plasma proteomic analysis in cancer cachexia would assist this effort and potentially lead to the 
identification of novel secretory pro-cachectic factors. In addition, it is unclear whether plasma 
proteomic analysis has been performed in disuse-induced atrophy. It is understood that the 
mechanism of muscle wasting is dependent on the etiology of the wasting. As such, this analysis 
would provide novel data that could improve our understanding of the mechanisms in disuse-
induced atrophy and potentially provide overarching targets that link the two forms of atrophy.   
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Purpose 
Therefore, the purpose of this thesis will be to examine the differential expression of 
circulating factors in cachectic and hindlimb suspended models utilizing proteomic 
methodologies to detect significantly modulated signaling pathways. Doing so will improve our 
knowledge of muscle atrophy by examining plasma proteomic profiles in pre-clinical models of 
muscle wasting and elucidating how signaling pathways interact with muscle tissue in atrophic 
states. 
Objectives of Data Analysis  
In order to further evaluate proteomic profiles in cancer cachexia and disuse-induced 
atrophy, this investigation will: 1) describe phonotypes of LLC-induced Cancer Cachexia and 
Hindlimb Suspended Animal, including body weight and tissue weight, 2) determine the number 
and identity of significantly modified proteins in plasma for cancer cachectic cohort in 
comparison to control, 3) determine the number and identity of significantly modified proteins in 
plasma for hindlimb suspended cohort in comparison to control, 4) determine the number and 
identity of significantly modified proteins in plasma for hindlimb suspended cohort in 
comparison to cancer cachectic cohort, 5) determine top pathways impacted by identified 





Chapter 2: Comparative Plasma Proteomics in Muscle Atrophy 
 Induced by Cancer Cachexia and Hindlimb Unloading 
Introduction 
Muscle atrophy, commonly referred to as muscle wasting, is a pathological dysfunction 
in protein turnover where an imbalance in protein synthesis and degradation leads to an overall 
loss in muscle mass and muscle function (32). Atrophy manifests in response to many diseases 
and disordered states. These pathologic stimuli trigger divergent responses in skeletal muscle. 
Inflammation—as observed in cancer, sarcopenia, chronic inflammatory disease, and sepsis—
predisposes fast-twitch, glycolytic muscle fibers to wasting (11, 18, 21, 35, 51, 56, 66). Whereas 
conditions of disuse, commonly not involving inflammation, such as denervation, forced bed 
rest, casting, and space flight, primarily affect slower twitch, oxidative fibers (4, 15, 48). Patients 
afflicted by atrophy experience increased rates of morbidity and mortality while their quality of 
life is significantly reduced (45). Currently, safe and efficacious therapeutic interventions to treat 
and prevent muscle wasting are lacking. To capture the breadth of this pathology, the present 
study will compare pre-clinical models of cancer cachexia and disuse-induced atrophy.   
Cancer cachexia is a multifactorial syndrome associated with an inflammatory 
microenvironment and characterized by an ongoing loss of skeletal muscle mass, with or without 
fat loss, that ultimately leads to impaired function (21). Cachexia is currently responsible for 
approximately 20%-40% of cancer-related deaths and patients with gastric or pancreatic cancers 
are especially prone to this complication (22, 23). Because this is a progressive form of wasting 
that cannot be reversed via nutritional means alone, it is valuable to consider cancer cachexia as 
a more complex metabolic disorder (29, 44). In fact, significant evidence suggests that protein 
anabolism is reduced in cachexia due to the down-regulation of several anabolic factors 
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including IGF-1, Akt, and mTOR (7, 11, 22, 50, 57, 59, 61, 69). Compounding this issue, the up-
regulation of cytokines, myostatin, FoxO, NF-ĸB, and PIF, coupled with other indirect measures 
of protein degradation, indicate an increased level of catabolism in cachectic muscle (2, 11, 22, 
50, 57, 58, 60, 69,72). Taken together, a decrease in protein anabolism and increase in 
catabolism contribute to a cachectic phenotype. Interestingly, evidence from our laboratory 
suggests that energy metabolism is also disrupted in cancer cachexia and mitochondrial 
dysfunction may even play an initiating role in this disease (1, 33, 40, 43, 49, 64, 73). 
Specifically, we observed a decrease in respiration, an increase in ROS production, and 
compromised mitochondrial network quality prior to the onset of cancer cachexia (10). Adding 
credence to our findings, increased Fis1 content has been corroborated in human studies (38). 
Collectively, evidence suggests many of the primary processes governing muscle mass 
maintenance are perturbed in cancer cachexia, ultimately shifting the muscle towards a catabolic 
state indefinitely. Fortunately, the involvement of these pathways presents many potential 
opportunities for therapeutic targets. 
Disuse-induced atrophy, associated with a lack of muscular tension, is a common 
consequence of forced bed-rest, limb casting, and space flight (4). Whether temporary or 
prolonged, disuse can have deleterious effects on force production and can increase mortality and 
morbidity (4). Although disuse atrophy does not manifest in an inflammatory cellular 
environment akin to cancer cachexia, dysfunctions in many of the same metabolic processes 
have been detected (48). For example, decreased rates of protein synthesis have been observed in 
disuse models and, from data suggesting rescued protein synthesis in DEPTOR knockdowns, this 
observation is likely due to the modulation of the mTOR axis (5, 34, 48, 54). In addition, indirect 
measures of catabolism suggest an increased catabolic rate, likely due to the up-regulation of 
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ubiquitin-proteasome markers MuRF1, Atrogin-1, FoxO, and FoxO3a (4, 5, 22, 58). 
Interestingly, energy metabolism and mitochondrial function have also been implicated in 
conditions of disuse (13, 14, 46). A reduction in oxidative capacity and decrease in 
mitochondrial fusion have both been observed (4, 46). As in cancer cachexia, these multiple 
dysfunctions disrupt protein balance and contribute to atrophy while also providing therapeutic 
opportunities. 
Proteomic profiles of biological fluids serve as valuable diagnostic tools and sources of 
therapeutic targets (19). Because cancer cachexia is a multi-organ syndrome affecting multiple 
organ systems including liver, adipose tissue, heart, and skeletal muscle, there is potential for 
cachectic muscle to be modulated via circulating factors (3, 67). In fact, evidence suggests that 
the pro-inflammatory cytokine IL-6 is up-regulated in the plasma of cachectic patients (9, 70). 
More so, the development of cachexia in murine models of colorectal cancer is largely dependent 
on IL-6 (6). Though cancer cachexia and disuse-induced atrophy target different muscles and 
develop secondary to different stimuli, the same metabolic processes are disrupted, providing a 
potential therapeutic link between the varying atrophic etiologies. To our knowledge, plasma 
proteomic analysis comparing cancer cachexia and disuse-induced atrophy has not been 
previously performed. Performing this global plasma proteomic analysis could lead to the 
identification of novel secretory pro-atrophic factors, provide novel data improving our 
understanding of the mechanisms in disuse-induced atrophy, and potentially reveal overarching 
targets linking the two forms of atrophy. Therefore, the purpose of this thesis will be to examine 
the differential content of circulating factors in cachectic and hindlimb suspended models of 
muscle atrophy utilizing proteomic methodologies to detect significantly modulated signaling 
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pathways. Doing so will improve our knowledge of muscle atrophy by elucidating how signaling 
pathways interact with muscle tissue in atrophic states.   
Methods 
Animals and Interventions 
All animal experiments were approved by the Institutional Animal Care and Use 
Committees of the University of Arkansas, Fayetteville. A cohort of male C57BL/6J mice were 
purchased from Jackson Laboratories. The animals were housed in a temperature-controlled 
room and maintained on a 12:12 h light-dark cycle. The mice were given ad libitum access to 
normal rodent chow and water.    
In the present study, we utilized two different pre-clinical models of muscle atrophy—
hindlimb suspension to recapitulate disuse-induced atrophy and Lewis Lung Carcinoma (LLC) 
implantation to induce cancer cachexia. A cohort of control animals was age matched to both 
experimental groups. All animals were singly housed to match housing requirements of hindlimb 
suspension.  
Lewis lung carcinoma culture and implantation  
Tumorigenic cells were prepared as previously described (10). Lewis lung carcinoma 
cells (ATCC CRL-1642) were plated at passage 2. Cells were cultured in 250 mL culture flasks 
in DMEM supplemented with 10% fetal bovine serum supplemented with 1% penicillin and 
streptomycin. Once cells reached confluency, they were trypsinized, counted, and diluted in PBS 
for implantation. Mice were anesthetized with isoflurane and hair was removed from the right 
hind flank. LLC cells (1x106) suspended in 100µL sterile PBS were injected subcutaneously into 
the hind flank of a single cohort of mice at 8 weeks of age as previously described. Tumors 
developed for approximately 3 weeks. Experimental endpoints were adjusted for excessive tumor 
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burden. Animals were anesthetized under isoflurane and body weight was recorded. Plantaris, 
gastrocnemius, soleus, extensor digitorum longus (EDL), tibialis anterior, quadriceps, spleen, 
epididymal fat, testes, and plasma were quickly collected post-euthanasia. Tissue samples were 
weighed and snap-frozen in liquid nitrogen for further processing and stored at -80ºC.       
Hindlimb Suspension 
Skeletal muscle disuse atrophy was induced by hindlimb suspension as previously 
described (39, 68). Mice were subjected to 7 days of hindlimb suspension. Mice were acclimated 
to handling by researchers for one week prior to unloading. Unanesthetized animals’ tails were 
cleansed with alcohol and betadine, covered with a small amount of benzoin tincture, and dried 
until the benzoin became tacky. A hair dryer was used to expedite the drying process. A strip of 
traction tape was wrapped around the base of the tail, just above the hairline. Tape was adjusted 
so that it did not impede blood circulation and provided an attachment site for the fish-line 
swivel device connected to the top of the cage. Mice were attached to a hindlimb suspension 
apparatus designed to allow access to all areas of the cage with only their forelimbs able to 
contact the cage floor. The unloading device used in our laboratory consists of a single rod that 
reaches across the cage. The rod has two rubber stoppers to restrain the mouse from moving too 
close to the cage walls and loading its hindlimbs. The fish-line swivel connects to a pulley 
system on the rod, allowing the mouse to move with minimal resistance along the rod between 
the rubber stoppers. The mouse is suspended at an angle of approximately 30 degrees so that the 
front legs are in contact with the cage floor and the hindlimbs are completely unloaded and 
unable to reach the floor. The floor is fitted with gridwire to prevent the animal from reloading 
its hindlimbs with piled up bedding.     
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A small amount of bedding was placed under the gridwire of each cage to absorb urine 
and waste. Animals were suspended for seven days and bedding materials were not replaced 
during the experiment. 
Animals were anesthetized under isoflurane and body mass was recorded. Plantaris, 
gastrocnemius, soleus, EDL, tibialis anterior, quadriceps, spleen, epididymal fat, testes, and 
plasma was quickly collected post-euthanasia. Tissue samples were weighed and snap-frozen in 
liquid nitrogen for further processing and stored at -80ºC.   
Proteomics 
Sample Collection 
Whole blood samples were obtained from animals under isoflurane anesthesia. Samples 
were centrifuged at 3.5 g for 15 minutes. Plasma was pipetted into separate sample tubes and 
stored at -80ºC. 100 µL plasma was aliquoted and sent to the University of Arkansas Medical 
Sciences’ Proteomics Facilities.   
Proteomics Analysis 
Tandem mass tag (TMT) proteomics was performed off-site (41). Once purified from 
plasma samples, proteins were reduced, alkylated, and digested using filter-aided sample 
preparation [Nature Methods 6: 359-62 (2009)]. Tryptic peptides were labeled using tandem 
mass tag isobaric labeling reagents (Thermo) according to the manufacturer’s instructions and 
combined into multiplex same groups. Normalization was achieved by including a pooled 
reference sample for each group. Labeled peptide multiplexes were divided into 36 fractions on a 
100 x 1.0 mm Acquity BEH C18 column (Waters) using an UltiMate 3000 UHPLC system 
(Thermo) with a 40 min gradient from 99:1 to 60:40 buffer A:B ratio. This was done under basic 
pH conditions. Samples were then consolidated into 12 super-fractions. The super-fractions were 
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further separated by reverse phase XSelect CSH C18 2.5 µm resin (Waters) on an in-line 150 x 
0.075 mm column using an UltiMate 3000 RSLCnano system (Thermo). Elution of the peptides 
was accomplished using a 60 min gradient from 97:3 to 60:40 buffer A:B ratio. Eluted peptides 
were ionized by electrospray (2.15 kV) followed by mass spectrometric analysis on an Orbitrap 
Fusion Lumos mass spectrometer (Thermo). MS3 parameters were used for this analysis. MS 
data was acquired using the FTMS analyzer in top-speed profile mode at a resolution of 120,000 
over a range of 375 to 1500m/z. Upon CID activation with normalized collision energy of 35.0, 
MS/MS data was acquired using the ion trap analyzer in centroid mode and normal mass range.  
Up to 10 MS/MS precursors were selected for HCD activation with normalized collision energy 
of 65.0 using synchronous precursor selection. This was followed by the acquisition of MS3 
reporter ion data using the FTMS analyzer in profile mode at a resolution of 50,000 over a range 
of 100-500 m/z. Protein identification and reporter ion quantification was accomplished using 
MaxQuant (Max Planck Institute) with a parent ion tolerance of 3 ppm, a fragment ion tolerance 
of 0.5 Da, and a reporter ion tolerance of 0.01 Da. Scaffold Q+S (Proteome Software) was used 
to verify MS/MS based peptide and protein identifications and to perform reporter ion-based 
statistical analysis. Protein identifications were accepted if they could be established with less 
than 1.0% false discovery and contain at least 2 identified peptides. Protein probabilities were 
assigned by the Protein Prophet algorithm [Anal. Chem. 75: 4646-58 (2003)]. 
Buffer A = 0.1% formic acid, 0.5% acetonitrile 
Buffer B = 0.1% formic acid, 99.9% acetonitrile 




Ingenuity Pathway Analysis (IPA; Qiagen, Valencia, CA; http://www.ingenuity.com) 
software was used for canonical pathway analysis, upstream analysis, and network discovery.   
Immunoblotting 
Immunoblotting was performed as we have previously described (10, 28, 37). 
Membranes were probed overnight with primary antibodies. Protein targets were selected based 
on the proteomic data provided by the UAMS Proteomics Core Facilities: SOD3 (R&D Systems 
AF4817) and Saa (R&D Systems AF2948). Primary antibodies were isolated from goat. 
Antibodies were diluted in Tris-buffered saline, 0.1% Tween 20 with 5% milk. Membranes were 
imaged on Protein Simple FluorChem (Minneapolis, MN). Images were analyzed via Alpha 
View software. All bands were normalized to the 25 kDa band of Ponceau S stain used as a 
loading control. Plasma was used for immunoblot analysis.        
Statistical Analysis 
Phenotypic and immunoblot data were analyzed with a one-way ANOVA and Tukey 
post-hoc test, α set at 0.05. Proteomic data were analyzed with a one-way ANOVA, α set at 0.05. 
Benjamini Hochberg correction adjusted α to 0.026. For proteomic analysis, differentially 
expressed proteins (DEP) were identified as surpassing threshold levels of p<0.026 and 
Log2FC = 0.6. All statistical analyses were performed with SAS software.    
Results 
Muscle atrophy induced by cancer cachexia and hindlimb unloading (Table 1.) 
Phenotypic descriptors of applicable body and tissue weights are presented in Table 1. 
Briefly, when we accounted for tumor mass, total LLC body weight was not significantly 
different from control or HU (p>0.05). Total HU body weight was significantly lower (8%) than 
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control (p<0.05). In both LLC and HU groups, raw plantaris, gastrocnemius, and quadriceps 
weights were significantly lower compared to control (. p<0.05). However, these weights were 
not significantly different between atrophic conditions (p>0.05). Soleus weight was lower in HU 
compared to control and LLC (33.4% and 23.2%, respectively), while LLC soleus weight was 
only significantly lower compared to control (13.2%, p<0.05). Wet spleen weight, a surrogate 
marker of inflammation, was ~200% greater in the LLC animals compared to control and HU 
(p<0.005). Equivalent tibia lengths across groups suggested no significant differences in body 
size.  
Global proteomics demonstrates largest differences in LLC-induced cancer cachexia (Table 2.) 
 Using TMT based discovery proteomics, a total of 369 peptides were identified in the 
plasma of the animals in this experiment. Following statistical comparison, 5 peptides were 
similarly modulated between LLC and HU groups and were significantly different compared to 
CON. Of those, 3 proteins including complement factor 1 (cf1), apolipoprotein B (ApoB), and 
coagulation factor IX (F9) were found to be higher in plasma from LLC and HU groups 
compared to CON. Conversely, 2 proteins were found to be lower in plasma from LLC and HU 
groups compared to CON including complement 7 (C7) and fibulin (Efemp1). However, while 
the contents of these proteins were statistically significant, they did not meet the Log2FC 
criterion to be considered DE. DE proteins discovered in each analysis are presented in Table 2. 
The comparison of LLC and HU plasma did yield 104 DE proteins. Of these, 44 were up-
regulated and 60 were down-regulated in LLC plasma compared to HU plasma. An evaluation of 
LLC and CON plasma resulted in 91 DE proteins—39 up-regulated and 52 down-regulated—in 
LLC plasma compared to CON. In the HU and control comparison, 5 up-regulated and 4 down-
regulated DE proteins were observed; a total of 9 DE proteins. 
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Pathway analysis of discovery proteomics (Tables 3-5, Figures 1-4) 
Canonical pathway analysis performed by IPA revealed several modulated pathways in 
each comparison (Tables 3-5, Figures 1-4). Currently, I am presenting the 5 most modulated 
pathways in each comparison. Commonly modulated processes among comparisons include 
acute phase response signaling, LXR/RXR activation, and FXR/RXR activation. In the LLC-HU 
analysis, these pathways were found to be most modulated in conjunction with atherosclerosis 
signaling and NO and ROS production in macrophages. The LLC-control comparison revealed 
additional modulations in atherosclerosis signaling and the intrinsic prothrombin activation 
pathway. Along with the commonly modulated pathways, the HU-control analysis resulted in 
modulations within the coagulation and complement systems. Most of these modulations do not 
clearly exhibit activation or inhibition of the pathway. However, IPA was able to predict activity 
in some these processes. Acute phase response signaling was up-regulated in LLC plasma 
compared to control and HU plasma (z-score: 2.714, 3.051, respectively). LXR/RXR activation 
was up-regulated in LLC compared to control and HU plasma (z-score: 0.5, 0.93, respectively). 
NO and ROS production in macrophages was down-regulated in LLC plasma compared to HU 
(z-score: -1.0), while intrinsic prothrombin activation was up-regulated in the same comparison 
(z-score: 0.447).  
Many DE proteins implicated in these modulated pathways exhibit predicted activity 
across multiple pathways and comparisons. 32 DE proteins, 19 up-regulated and 13 down-
regulated, were involved in the LLC-HU comparison. 27 DE proteins, 16 up-regulated and 11 
down-regulated, were implicated in the LLC-CON comparison. 7 DE proteins, 3 up-regulated 
and 4 down-regulated, were found in the HU-control analysis. The protein Serum Amyloid A 
(SAA), implicated in acute phase response signaling, LXR/RXR and FXR/RXR activation, were 
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involved in every comparison and were the most modulated. Interestingly, SAA responded to 
atrophy in a divergent manner, being up-regulated in LLC plasma and down-regulated in HU 
plasma (Log2FC: 4.17 LLC, -2.16 HU). Apolipoproteins, Fibrinogens, SerpinA3, SerpinF1, 
PON1, antioxidant proteins, and others were found to be predominantly modulated in LLC 
plasma. Similarly, SAA, SerpinA1 and Fibrinogens were predominantly modulated in HU 
plasma. 
Immunoblot confirmation of plasma proteomics  
 Immunoblot analysis was used to confirm plasma proteomics findings. According to our 
proteomics data, SAA was highly expressed in LLC plasma and repressed in HU plasma. 
Immunoblot analysis confirmed higher SAA expression in LLC plasma compared to CON. 
However, because signals were not present in CON or HU samples, we cannot confirm that SAA 
expression in HU plasma was suppressed compared to CON (Figure 5). This blot was not 
quantified as SAA signal was only detected in LLC and internal control samples.  
Proteomics analysis suggests catalase content was lower in LLC samples compared to 
HU plasma. SOD3 was probed as an anti-oxidant surrogate to catalase as the molecular weight of 
catalase overlays albumin, thereby making the catalase signal indistinguishable. Immunoblot 
analysis did not reveal any significant differences in SOD3 content between LLC plasma and 
other conditions (p>0.05). However, mean SOD3 content was lower in LLC plasma compared to 
HU and CON (Figure 6).         
Discussion 
 Our study is among the first to compare modulations in plasma proteomes in disuse-
induced atrophy and cancer cachexia. Current literature has established that muscle atrophy, 
secondary to cancer cachexia or disuse, involves several metabolic processes that shifts the 
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muscle towards a catabolic state (11, 60, 62, 69, 72). Additionally, elevated plasma IL-6 levels in 
cancer cachexia patients suggest a possible link between the plasma proteome and muscle 
wasting (71). Prior observations made by Baltgalvis et al. (6) demonstrated muscle mass was 
dependent on IL-6 signaling in cancer cachexia development in the ApcMin/+ mouse model of 
colorectal cancer; therefore, circulating factors may be regulating key regulators of muscle mass 
in atrophic conditions. In an effort to identify atrokines, differing and similar among etiologies of 
muscle atrophy, the present study compared plasma proteomes across disuse-induced atrophy 
and LLC-induced cancer cachexia and suggests if muscle mass is a function of circulating 
factors, conditions are modulated independently of one another. The proteomic profiles predict 
up-regulated acute phase response signaling, LXR/RXR activation, and intrinsic prothrombin 
activation and a down-regulation in NO and ROS production in macrophages in LLC plasma. 
However, the proteomic profiles predict a down-regulation of acute phase response signaling in 
HU plasma. Moreover, LLC plasma possessed approximately 10 times more DE proteins than 
HU plasma, further suggesting a greater reliance of cancer cachexia atrophy on the plasma 
proteome than under conditions of disuse. Our findings present circulating factors as potential 
atrophic modulators, specifically under cachectic conditions. Furthermore, to our knowledge, we 
are the first to perform global proteomic analysis in disuse-induced atrophy. The data herein 
demonstrate the need for continued investigation of plasma’s role in influencing muscle in 
atrophic etiologies.  
Modulated pathways observed in atrophic plasma may influence muscle mass 
Canonical pathway analysis suggests the involvement of several pathways in muscle 
atrophy. In all comparisons, acute phase response signaling, LXR/RXR activation, and 
FXR/RXR activation were modulated. LLC plasma exhibited an up-regulation of acute phase 
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response signaling LXR/RXR activation and down-regulation of NO and ROS production in 
macrophages compared to HU. In addition, intrinsic prothrombin activation was altered in LLC 
plasma compared to control, and the coagulation and complement systems were modulated in 
HU plasma compared to control. Upstream analyses of these comparisons provided by IPA 
identifies key proteins affected by the modulations in atrophic plasma and shed light on potential 
plasma-muscle interactions.  
Commonly modulated pathways 
Acute Phase Response 
The acute phase response is associated with a rapid inflammatory response that can be 
triggered by many stimuli including neoplastic growth, or tumor development. This response is 
associated with fever and an increased concentration of pro-inflammatory cytokines, which is 
largely due to changes in hepatic metabolism (Appendix). In particular, the cytokines IL-6, 
IL1B, and OSM were predicted to be activated in our analysis, in addition to the STAT3 
complex. Several modulated LLC markers observed in our study including down-regulated ALB, 
APOA1/2, TTR, RBP4, CAT, and up-regulated fibrinogens, SAA, C4A/C4B. APCS, 
SERPINA1, HPX, HP, SERPINF, ITIH3, and ITIH4 are all consistent with this observation. IL-
6 is a known regulator of muscle mass in some forms of cancer cachexia (6, 70, 71). It has been 
suggested to contribute to catabolism by increasing ubiquitin-proteasome activity and reducing 
activity of anabolic processes (70).  Moreover, in a C26 cachexia model, Bonetto et al. (8) have 
observed elevated IL-6/STAT3 transcription in skeletal muscle that was associated with the 
expression and secretion of additional acute phase response proteins into the plasma, suggesting 
a muscle-plasma interaction and a potential paracrine function of muscle in cachexia. While IL-6 
plays a role in cancer cachexia, other modulated proteins identified in this study have exhibited 
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atrokine activity as well. SAA, the most modulated protein observed here, has been implicated in 
COPD mediated muscle wasting. Passey et al. (42) observed SAA was sufficient to induce 
atrophy via pro-inflammatory signaling in the Toll-like receptor 2. In addition, under healthy 
conditions, catalase functions as an antioxidant responsible for managing concentrations of 
intracellular ROS produced by mitochondria. Selsby et al. (52) observed that overexpression of 
catalase in mice with Duchenne’s muscular dystrophy improved muscle function, suggesting 
improved antioxidant capacity may ameliorate wasting associated with inflammation and excess 
ROS production. It is worth noting that prior work done in our laboratory suggests that 
mitochondrial dysfunction precedes wasting in LLC-induced cancer cachexia and in our present 
analysis, catalase content is lower in LLC plasma compared to CON. These observations make 
SAA and catalase potential therapeutic targets. In addition, our analysis identified the 
involvement of various SERPINS. Interestingly, SERPINA3s have been associated with bovine 
apoptotic control via caspase inhibition which is important for muscle cell survival and myoblast 
differentiation during repair (25). Our analysis revealed that in LLC plasma, some SERPINA3 
isoforms are up-regulated while others are down-regulated. This control mechanism presents a 
unique opportunity and provides us another potential therapeutic target. In HU, our findings 
demonstrated a down-regulation of this acute phase response pathway, suggesting that disuse-
induced atrophy is mediated in a different fashion.   
LXR/RXR and FXR/RXR Activation 
 LXR is a hepatic receptor that forms a heterodimer with RXR and is involved in the 
regulation of lipid metabolism, inflammation, and cholesterol metabolism. In the up-regulated 
state, as observed in LLC plasma, the LXR/RXR pathway increases cholesterol metabolism, 
cholesterol biosynthesis, cholesterol transport, lipoprotein synthesis, lipogenesis, and cholesterol 
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efflux from hepatocytes (Appendix). In macrophages, up-regulated LXR/RXR is associated with 
a proliferated immune response. FXR/RXR is related to the LXR/RXR pathway and serves as a 
regulator of bile acid levels. FXR regulates metabolic processes by linking bile acid regulation 
with lipoprotein, lipid, and glucose metabolism (Appendix). In our analysis, this regulation of 
metabolism coincided with a decrease in apolipoprotein content in LLC plasma. Little is known 
about these pathways’ contributions to skeletal muscle mass, but due to overlaps in the DE 
protein profiles for acute phase response and atherosclerosis signaling, it is possible that 
LXR/RXR and FXR/RXR modulation may influence skeletal muscle in an indirect manner. To 
our knowledge, work has yet to be done connecting LXR/RXR and FXR/RXR activity to 
cachexia, but their contribution to lipid metabolism make them possible influencers of fat mass, a 
loss of which is commonly associated with the cachectic phenotype, also observed here. While 
we did see modulations in these pathways in HU plasma, up or down-regulation could not be 
predicted, suggesting that links between HU and LLC plasma are lacking in these pathways.  
Pathways modulated specifically in LLC 
In LLC plasma, atherosclerosis signaling, NO and ROS production in macrophages, and 
intrinsic prothrombin activity were modulated. Atherosclerosis signaling was not found to be up 
or down-regulated in LLC plasma. Literature suggests that peripheral atherosclerosis can have 
negative consequences for muscle (53). These alterations include increased oxidative stress, 
increased inflammatory signaling, mitochondrial dysfunction, altered myofiber morphology, 
fibrosis, ischemia, and apoptosis (53). Our findings, while not conclusive in determining the 
direction of modulation, suggest atherosclerotic signaling has the potential to indirectly 
contribute to atrophy.  
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NO and ROS production in macrophages was down-regulated in LLC plasma, due to 
modulations in proteins such as catalase. The down-regulation of catalase negatively impacts NO 
and ROS production in macrophages. This decrease in NO and ROS impairs the macrophage’s 
ability to perform standard functions such as responding to infection and neoplasia (65). 
Dysfunctional macrophages may indirectly impact muscle mass. In addition to responding to 
infection and inflammatory responses, macrophages are needed to debride damaged myofiber 
debris and secrete regenerative factors that promote the activation and incorporation of satellite 
cells into areas of muscle damage (65). This pathway presents another potential indirect 
modulator of cancer cachexia.  
Intrinsic prothrombin activity was upregulated in LLC plasma. Deguchi et al. (17) 
suggest that myosin can directly influence thrombosis and coagulation of the blood and they 
observed higher levels of thrombotic factors in cases of acute trauma. Therefore, it appears that 
our finding of up-regulated prothrombin activity does not enhance atrophy, but instead is likely 
due to the interaction of inflamed, traumatized muscle and plasma.          
Pathways modulated specifically in HU 
In HU plasma, we found modulations in acute phase response signaling, LXR/RXR and 
FXR/RXR activation, the coagulation system, and the complement system. Of these, only the 
acute phase response signaling pathway was predicted to be down-regulated. Other modulations 
were deemed neutral. Shifts in the coagulation system were detected. Frigeri et al. (24) also made 
this observation and surmised this result to fluid shifts induced by hindlimb unloading. 
Therefore, this finding is probably not due to the interaction of plasma and skeletal muscle, but 
more likely an artifact of our HU protocol. Similarly, the complement system—an aspect of the 
immune system—was found to be modulated in HU plasma. This system is necessary for the 
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lysis of foreign cells, clearance of immune complexes, and activation of inflammation and 
augmentation of the antibody response. Other studies suggest that immune system sensitivity is 
likely reduced in this condition due to stress (24, 27) While coagulation and complement systems 
serve vital roles, it is unclear whether there is an interaction between these systems, HU plasma, 
and HU muscle that could exacerbate atrophy. Instead it appears these observed modulations are 
the result of the stress and fluid shift induced via hindlimb suspension.    
Protein modulation in HU 
 In our analysis, a total 9 DE proteins were detected in HU plasma and of those, 7 were 
found to be implicated in highly impacted pathways. This small pool of proteins may represent 
potential circulating atrokines associated with disuse-induced atrophy. The most promising of 
these targets include Fibrinogen 1 (FN1) and SAA. We observed higher content of FN1 and 
lower content of SAA in HU plasma compared to CON. Fibrinogen 1 is a marker commonly 
associated with many diseases and Ueki et al. (63) observed that in atrophy induced by burn 
injury, elevated fibrinogen was associated with increased inflammation and decreased 
mitochondrial quality. When they used a toll-like receptor inhibiting treatment that impaired 
fibrinogen’s action, mitochondrial health improved, as did burn injury survival rate. 
Interestingly, in disuse-induced atrophy, mitochondrial dysfunction has also been observed. 
Increased ROS production, impaired Ca2+ handling, and the release of proteolytic activators all 
promote atrophy, making Fibrinogen 1 a potential therapeutic target (46). In LLC plasma, up-
regulated SAA contributes to atrophy via increasing IL-6 and TNF-α signaling and increasing 
induction of Atrogin-1. When exacerbated, IL-6 signaling and Atrogin-1 can have deleterious 
effects on muscle mass (42). However, IL-6 and Atrogin-1 are required for healthy muscle 
maintenance (40, 73). IL-6 is associated with hypertrophic muscle growth and the regulation of 
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energy metabolism and, in the proper concentrations, Atrogin-1 contributes to mitophagy which 
allows the mitochondrial network to remove damaged mitochondria and preserve network 
quality. In our analysis of HU plasma, SAA is significantly down-regulated, possibly suggesting 
that a threshold of SAA expression is required for muscle mass maintenance.       
Conclusions and Future Direction 
In summary, this is the first study to investigate a comparison of plasma proteomes in 
disuse-induced atrophy and cancer cachexia. Several proteins were found to be modulated in 
atrophic conditions, though more aberrations to the plasma proteome were detected in cachectic 
compared to disuse atrophy. This observation is consistent with a greater reliance of cachexia on 
bloodborne signaling as compared to disuse. These DE proteins influenced the activity of many 
signaling pathways including acute phase response signaling and LXR/RXR and FXR/RXR 
activation. Up-regulated acute phase response signaling in cancer cachexia likely up-regulates 
IL-6/STAT3 expression which would cause muscle to secrete additional acute phase proteins, 
thereby exacerbating cachexia signals. Interestingly, this finding supports a muscle-plasma 
interaction and highlights muscle as a potential paracrine organ in cachexia. A down-regulation 
in this same pathway in HU plasma indicates that these etiologies develop independently of each 
other. Although future studies are warranted to validate these relationships. To accomplish this, 
future experiments should evaluate proteomic profiles in the muscle to verify predicted muscle-
plasma interactions. This study highlights a clear need for the further study of plasma-muscle 
interactions in muscle atrophy.          
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Appendix 
Table 1. Body and wet tissue weights at time of harvest in control (CON), hindlimb-unloaded 
(HU), and Lewis lung carcinoma tumor-bearing mice (LLC). N of 10-14/group was utilized. 
Tibia length was used as an estimate of total body size. Tibia length did not differ between 
groups; therefore, all tissue weights are presented as non-normalized wet weights. Lettering 
denotes statistical significance between groups, alpha set at p<0.05. 
 
Group CON (N=10) LLC (N=14) HU (N=10) 
Body Weight (g) 26.06 + 0.47 a 26.96 + 0.4 a 23.99 + 0.46 b 
Tumor (g) NA 1.84 + 0.18 NA 
Body Weight - Tumor (g) 26.06 + 0.47a 25.12 + 0.43a 23.99 + 0.46b 
Soleus (mg)  10.07 + 0.25 a 8.74 + 0.27 b 6.71 + 0.25 c 
Plantaris (mg)  21.09 + 0.66 a 16.31 + 0.4 b 17.17 + 0.48 b 
Gastrocnemius (mg) 131.51 + 1.76 a 119.9 + 2.36 b 114.03 + 2.23 b 
EDL (mg) 10.84 + 0.43 9.66 + 0.2 10.48 + 0.48 
TA (mg) 49.41 + 1.0 a 44.15 + 0.89 b 46.47 + 0.99 a 
Quadriceps (mg) 193.71 + 8.58 a 141.31 + 10.15 b 156.89 + 8.09 b 
Spleen (mg) 69.05 + 1.89 a 164.52 + 12.07 b 63.44 + 9.97 a 
Gonadal Fat (mg) 532.16 + 39.94 a 351.03 + 16.27 b 289.17 + 20.83 b 
Testes (mg) 114.91 + 2.98 109.82 + 2.64 113.09 + 3.46 




Table 2. Differentially expressed (DE, statistical significance p<0.026, Log2FC > 0.6) proteins 








Total DE Proteins 
LLC-HU 44 60 104 
LLC-CON 39 52 91 
HU-CON 5 4 9 
3
8
A) B)       C) 
Figure 1. Percent of modulated molecules in the most affected pathways. A) Modulated molecules in the LLC-HU 
comparison. Z-scores for acute phase response: 3.051, LXR/RXR activation: 0.943, NO and ROS production in macrophages: 
-1.00. B) Modulated molecules in the LLC-CON comparison. Z-scores for acute phase response: 2.714, LXR/RXR activation:
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Figure 4. DE proteins involved in the 5 most modulated pathways in the HU-CON comparison. 






























Figure 5. Confirmation immunoblot analysis. A) Representative immunoblot images of SAA 
and SOD3. B) Quantification of SOD3 blot normalized to Ponceau S stain.     
Group





















Supplemental Figure 3. FXR/RXR activation pathway (Wolf et al., 2013). 
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